Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception

Susie E. Huntington*, Loveleen K. Bansi, Claire Thorne, Jane Anderson, Marie Louise Newell, Graham P. Taylor, Deenan Pillay, Teresa Hill, Pat A. Tookey, Caroline A. Sabin

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    12 Citations (Scopus)

    Abstract

    Objectives: To describe antiretroviral therapy (ART) use and clinical status, at start of and during pregnancy, for HIV-positive women receiving ART at conception, including the proportion conceiving on drugs (efavirenz and didanosine) not recommended for use in early pregnancy. Methods: Women with a pregnancy resulting in a live-birth after 1995 (n = 1537) were identified in an observational cohort of patients receiving HIV care at 12 clinics in the UK by matching records with national pregnancy data. Treatment and clinical data were analysed for 375 women conceiving on ART, including logistic regression to identify factors associated with changing regimen during pregnancy. Results: Of the 375 women on ART, 39 (10%) conceived on dual therapy, 306 (82%) on triple therapy and 30 (8%) on more than three drugs. In total, 116 (31%) women conceived on a regimen containing efavirenz or didanosine (69 efavirenz, 54 didanosine, seven both). Overall, 38% (143) changed regimen during pregnancy, of whom 44% (n = 51) had a detectable viral load around that time. Detectable viral load was associated with increased risk of regimen change [adjusted odds ratio 2.97, 95% confidence interval (CI) (1.70-5.19)], while women on efavirenz at conception were three times more likely to switch than women on other drugs [3.40, (1.84-6.25)]. Regimen switching was also associated with year at conception [0.89, (0.83-0.96)]. Conclusion: These findings reinforce the need for careful consideration of ART use among women planning or likely to have a pregnancy in order to reduce viral load before pregnancy and avoid drugs not recommended for early antenatal use.

    Original languageEnglish
    Pages (from-to)1647-1655
    Number of pages9
    JournalAIDS
    Volume25
    Issue number13
    DOIs
    Publication statusPublished - 24 Aug 2011

    Keywords

    • HIV
    • United Kingdom
    • antiretroviral agents
    • antiretroviral therapy
    • pregnancy

    Fingerprint

    Dive into the research topics of 'Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception'. Together they form a unique fingerprint.

    Cite this